Your cart
Your cart is empty.HEALTH NEWS
Study Title:
Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1
Study Abstract
This database study examines the association between glucagon-like peptide 1 agonists (eg, semaglutide, liraglutide) used for weight loss and reports of gastrointestinal adverse events.
Study Information
JAMA. 2023 Nov 14;330(18):1795-1797. doi: 10.1001/jama.2023.19574. PMID: 37796527; PMCID: PMC10557026.
Full Study
https://pubmed.ncbi.nlm.nih.gov/37796527/Recent News
Pterostilbene: A Timeless Health Tonic for Longevity and Vitality
Astaxanthin for Healthier, Hydrated, and Resilient Skin
Arabinogalactan Boosts Lymph Flow and Immunity
Protect Your Gut Mucosal Barrier for Immune Health and Vitality
The Truth About Sugar Substitutes: Are Stevia, Sucralose, and Saccharin Safe?
Super Sale Is Here!
20% off 1-9 supplements
25% off 10-14 supplements
30% off 15+ supplements